公开(公告)号：US20240271105A1

公开(公告)日：2024-08-15

申请号：US18692146

申请日：2022-09-16

Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA

Inventor： Timothy D. O'Brien ,  Beth Lindborg ,  Amanda Vegoe ,  Yi Wen Chai ,  Manci Li

IPC: C12N5/071 ,  A61K35/32 ,  A61P19/02

CPC classification number: C12N5/0697 ,  A61K35/32 ,  A61P19/02 ,  C12N2500/30 ,  C12N2506/45

Abstract: A method for producing a multi-tissue organoid generally includes obtaining pluripotent stem cells (PSCs) and inducing growth of the multi-tissue organoid by culturing the harvested PSCs in suspension in a culture vessel. Another method for producing a multi-tissue organoid generally includes introducing a pluripotent stem cell into a cell culture medium comprising hyaluronic acid, transferring the pluripotent stem cell to a cell culture device that does not include a three-dimensional matrix, culturing the pluripotent stem cell in the cell culture device for at least 1 week, and producing a multi-tissue organoid comprising cartilage, bone, fibrous connective tissue, brain tissue, or epithelial tissue, or a combination thereof.

公开(公告)号：US20240192229A1

公开(公告)日：2024-06-13

申请号：US18286682

申请日：2022-04-15

Applicant: Regents of the University of Minnesota

Inventor： Peter C. Christenson ,  Gage Rowden ,  Sang-Hyun Oh ,  Peter A. Larsen ,  Manci Li

IPC: G01N33/68 ,  G01N33/58

CPC classification number: G01N33/6896 ,  G01N33/587 ,  G01N2800/2821 ,  G01N2800/2828 ,  G01N2800/2835

Abstract: This document relates to methods and materials for detecting the presence or absence of misfolded polypeptides in a sample. For example, methods and materials for amplifying a sample (e.g., a biological sample or an environmental sample) such that misfolded polypeptides present in the sample can aggregate to form fibrils and/or globular polypeptide aggregates and contacting the amplified sample with a solution containing metal nanoparticles (e.g., gold nanoparticles) or one or more organic dyes (e.g., Congo Red) to detect the presence or absence of fibrils and/or globular polypeptide aggregates are provided. In some cases, methods and materials for determining if a mammal (e.g., a human) has a proteinopathy based, at least in part, in the presence or absence of misfolded polypeptides in a sample obtained from the mammal are provided.